{"protocolSection": {"identificationModule": {"nctId": "NCT01294553", "orgStudyIdInfo": {"id": "105709"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVANDAMET Between June 2004 and January 2010", "officialTitle": "An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of Avandamet\u00ae Administered in Korean Diabetic Patients According to the Prescribing Information", "acronym": "AVANDAMETPMS"}, "statusModule": {"statusVerifiedDate": "2011-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2004-06"}, "primaryCompletionDateStruct": {"date": "2010-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-02-10", "studyFirstSubmitQcDate": "2011-02-10", "studyFirstPostDateStruct": {"date": "2011-02-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-02-17", "resultsFirstSubmitQcDate": "2011-02-17", "resultsFirstPostDateStruct": {"date": "2011-03-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-06-07", "lastUpdatePostDateStruct": {"date": "2017-07-07", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of rosiglitazone/metformin administered in Korean Diabetic patients according to the prescribing information", "detailedDescription": "An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of rosiglitazone/metformin administered in Korean Diabetic patients according to the prescribing information"}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"observationalModel": "OTHER", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 717, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "rosiglitazone/metformin group", "description": "Korean subjects who are administered rosiglitazone/metformin according to the prescription information", "interventionNames": ["Drug: Administration of rosiglitazone/metformin"]}], "interventions": [{"type": "DRUG", "name": "Administration of rosiglitazone/metformin", "description": "Subjects who are administered rosiglitazone/metformin at least once", "armGroupLabels": ["rosiglitazone/metformin group"], "otherNames": ["according to label and physician's decision based on each subject's condition"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With an Adverse Event", "description": "An adverse event is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. For a list of all adverse events occurring during the course of the study, please see the table entitled \"Other (non-serious) adverse events\" in the Adverse Event section of the results record.", "timeFrame": "41.4 weeks"}], "secondaryOutcomes": [{"measure": "Number of Participants With a Serious Adverse Event", "description": "A serious adverse event is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or results in prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. For a list of all serious adverse events occurring during the course of the study, please see the table entitled \"Serious Adverse Events\" in the Adverse Event section of the results record.", "timeFrame": "41.4 weeks"}, {"measure": "Number of Participants With the Indicated Unexpected Adverse Events", "description": "Unexpected adverse events are defined as those that were not described in the locally approved label by the Korean Food and Drug Administration (KFDA) at the time of surveillance completion.", "timeFrame": "41.4 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria\n\n* Subjects administered with rosiglitazone/metformin as an adjunct to diet and exercise for the treatment of type2 diabetes mellitus\n* Subjects who the investigator believes that they can and will comply with the requirements of the protocol and follow the administration regimen\n* Subjects administered with rosiglitazone/metformin following the locally approved prescribing information\n\nExclusion criteria\n\n* Subjects with previous history of hypersensitivity to rosiglitazone and/or metformin or any other ingredient\n* Subjects with previous history of lactic acidosis, renal disease or renal dysfunction, hepatic dysfunction, cardiogenic shock, heart failure, myocardial infarction, pulmonary infarction and any other status with stomach upset\n* Subjects with type 1 diabetes mellitus\n* Subjects with acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma\n* Subjects with severe infection, pre/post surgery, severe trauma\n* Subjects with malnutrition, inanition, emaciation, pituitary insufficiency, adrenal insufficiency\n* Subjects undergoing radiologic studies involving intravascular administration of iodinated contrast materials", "healthyVolunteers": false, "sex": "ALL", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "Type II diabets mellitus patients prescribed rosiglitazone/metformin in general hospital", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "The objective of this post-marketing surveillance (PMS) study was to monitor the safety and efficacy of Avandamet in the real clinical setting after launch.", "groups": [{"id": "FG000", "title": "Avandamet 1/500, 2/500, 4/500, 2/1000, or 4/1000 mg", "description": "Participants were assigned to the appropriate dose of Avandamet tablet based on their current regimen (fixed dose combination of rosiglitazone and metformin, 1/500 milligrams \\[mg\\], 2/500 mg, 4/500 mg, 2/1000 mg, or 4/1000 mg). Participants were not to have exceeded the maximum recommended daily dose of 8/2000. All participants were to have started the rosiglitazone component of Avandamet at the lowest recommended dose, and all dose increases should have been accompanied by careful monitoring for adverse events related to fluid retention."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "982"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "713"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "269"}]}], "dropWithdraws": [{"type": "Duplicated Participants", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "268"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Avandamet 1/500, 2/500, 4/500, 2/1000, or 4/1000 mg", "description": "Participants were assigned to appropriate dose of Avandamet tablet (fixed dose combination of rosiglitazone and metformin, 1/500 milligrams \\[mg\\], 2/500 mg, 4/500 mg, 2/1000 mg, or 4/1000 mg) per physician's decision based on participant's condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "713"}]}], "measures": [{"title": "Age, Continuous", "description": "Baseline characteristics were collected in members of the Intent-to-Treat (ITT) Population, comprised of all participants who had been administered the investigational drug at least once and had undergone all safety assessments.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.4", "spread": "11.5"}]}]}]}, {"title": "Sex: Female, Male", "description": "Baseline characteristics were collected in members of the ITT population, comprised of all participants who had been administered the investigational drug at least once and had undergone all safety assessments.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "369"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "344"}]}]}]}, {"title": "Race/Ethnicity, Customized", "description": "Baseline characteristics were collected in members of the ITT Population, comprised of all participants who had been administered the investigational drug at least once and had undergone all safety assessments.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Korean", "categories": [{"measurements": [{"groupId": "BG000", "value": "713"}]}]}, {"title": "Not Korean", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With an Adverse Event", "description": "An adverse event is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. For a list of all adverse events occurring during the course of the study, please see the table entitled \"Other (non-serious) adverse events\" in the Adverse Event section of the results record.", "populationDescription": "Intent-to-Treat (ITT) Population: all participants who had been administered the investigational drug at least once and had undergone all safety assessments", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "41.4 weeks", "groups": [{"id": "OG000", "title": "Avandamet 1/500, 2/500, 4/500, 2/1000, or 4/1000 mg", "description": "Participants were assigned to appropriate dose of Avandamet tablet (fixed dose combination of rosiglitazone and metformin, 1/500 milligrams \\[mg\\], 2/500 mg, 4/500 mg, 2/1000 mg, or 4/1000 mg) per physician's decision based on participant's condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "713"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "110"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Percentage of participants", "paramValue": "15.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "12.8", "ciUpperLimit": "18.1", "estimateComment": "The estimated value represents the percentage of participants with an adverse event."}]}, {"type": "SECONDARY", "title": "Number of Participants With a Serious Adverse Event", "description": "A serious adverse event is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or results in prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. For a list of all serious adverse events occurring during the course of the study, please see the table entitled \"Serious Adverse Events\" in the Adverse Event section of the results record.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "41.4 weeks", "groups": [{"id": "OG000", "title": "Avandamet 1/500, 2/500, 4/500, 2/1000, or 4/1000 mg", "description": "Participants were assigned to appropriate dose of Avandamet tablet (fixed dose combination of rosiglitazone and metformin, 1/500 mg, 2/500 mg, 4/500 mg, 2/1000 mg, or 4/1000 mg) per physician's decision based on participant's condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "713"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With the Indicated Unexpected Adverse Events", "description": "Unexpected adverse events are defined as those that were not described in the locally approved label by the Korean Food and Drug Administration (KFDA) at the time of surveillance completion.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "41.4 weeks", "groups": [{"id": "OG000", "title": "Avandamet 1/500, 2/500, 4/500, 2/1000, or 4/1000 mg", "description": "Participants were assigned to appropriate dose of Avandamet tablet (fixed dose combination of rosiglitazone and metformin, 1/500 mg, 2/500 mg, 4/500 mg, 2/1000 mg, or 4/1000 mg) per physician's decision based on participant's condition"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "713"}]}], "classes": [{"title": "Gastritis", "categories": [{"measurements": [{"groupId": "OG000", "value": "42"}]}]}, {"title": "Dysaesthesia", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}]}]}, {"title": "Impotence", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Paralysis", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Insomnia", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Depression", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Dermatitis", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Peptic ulcer", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Gastric ulcer", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Temperature changed sensation", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Dermatitis fungal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Pneumonia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Skeletal pain", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Osteoporosis", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Myalgia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Anxiety", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Cystitis", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Renal calculus", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Albuminuria", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Urinary incontinence", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Liver fatty", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Vaginal haemorrhage", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Menopausal symptoms", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Glaucoma", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Coughing", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Exophthalmus", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Teratoma benign", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Cardiomyopathy", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Arteriosclerosis", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0.4", "description": "Adverse events were coded by using World Health Organization Adverse Reactions Terminology (WHOART, preferred term level) according to the local regulation.", "eventGroups": [{"id": "EG000", "title": "Avandamet 1/500, 2/500, 4/500, 2/1000, or 4/1000 mg", "description": "Participants were assigned to appropriate dose of Avandamet tablet (fixed dose combination of rosiglitazone and metformin, 1/500 milligrams \\[mg\\], 2/500 mg, 4/500 mg, 2/1000 mg, or 4/1000 mg) per physician's decision based on participant's condition", "seriousNumAffected": 2, "seriousNumAtRisk": 713, "otherNumAffected": 77, "otherNumAtRisk": 713}], "seriousEvents": [{"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "WHOART", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 713}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "WHOART", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 713}]}, {"term": "Pneumonia", "organSystem": "Immune system disorders", "sourceVocabulary": "WHOART", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 713}]}], "otherEvents": [{"term": "Upper respiratory tract infection", "organSystem": "Immune system disorders", "sourceVocabulary": "WHOART", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 713}]}, {"term": "Oedema", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "WHOART", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 713}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "WHOART", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 713}]}, {"term": "Weight increase", "organSystem": "General disorders", "sourceVocabulary": "WHOART", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 713}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "WHOART", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 713}]}, {"term": "Headache", "organSystem": "General disorders", "sourceVocabulary": "WHOART", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 713}]}, {"term": "Dysaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "WHOART", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 713}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "WHOART", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 713}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "WHOART", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 713}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "WHOART", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 713}]}, {"term": "Back Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "WHOART", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 713}]}, {"term": "Impotence", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "WHOART", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 713}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077154", "term": "Rosiglitazone"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M1677", "name": "Rosiglitazone", "asFound": "Facility", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}